Copyright
©The Author(s) 2022.
World J Clin Cases. Nov 26, 2022; 10(33): 12156-12163
Published online Nov 26, 2022. doi: 10.12998/wjcc.v10.i33.12156
Published online Nov 26, 2022. doi: 10.12998/wjcc.v10.i33.12156
Table 1 Baseline characteristics of patients
| Variables | TACE-RFA (n = 64) | TACE (n = 38) | P value |
| Sex (male/female) | 51/13 | 33/5 | 0.359 |
| Age (yr) | 53.0 ± 9.5 (25-72) | 52.7 ± 8.5 (39-75) | 0.876 |
| HBsAg (+/-) | 54/10 | 35/3 | 0.409 |
| HCV (+/-) | 3/61 | 4/34 | 0.470 |
| ALB (g/L) | 38.1 ± 4.6 (25.0-53.0) | 36.4 ± 5.8 (25.0-52.0) | 0.103 |
| AFP/(ng/mL) | 0.628 | ||
| < 400 | 11 | 8 | |
| ≥ 400 | 53 | 30 | |
| Child-Pugh class | 0.036 | ||
| A | 51 | 23 | |
| B | 13 | 15 | |
| Tumour number | 0.987 | ||
| < 3 | 22 | 13 | |
| 3 | 42 | 25 | |
| TBIL (μmol/L) | 18.2 ± 7.9 (4.9-49.5) | 21.2 ± 9.2 (5.3-45.3) | 0.081 |
| Max-diameter (cm) | 9.5 ± 3.1 (5.0-18.0) | 10.2 ± 3.5 (5.1-17.0) | 0.267 |
- Citation: Sun SS, Li WD, Chen JL. Transarterial chemoembolization combined with radiofrequency ablation in the treatment of large hepatocellular carcinoma with stage C. World J Clin Cases 2022; 10(33): 12156-12163
- URL: https://www.wjgnet.com/2307-8960/full/v10/i33/12156.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i33.12156